Hester Biosciences Limited has received formal requests from two promoter-category shareholders — Mr. Ravin Gandhi and Ms. Bela Gandhi — seeking reclassification to the "Public" category under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The requests were submitted vide letters dated 14 May 2026, and the company disclosed this development to the stock exchanges on 15 May 2026 in compliance with Regulation 31A(8) of the SEBI (LODR) Regulations, 2015. The company has stated that it is undertaking all necessary steps to process these requests in accordance with applicable regulatory provisions.

Reclassification Request Details

The two individuals seeking reclassification, along with their respective shareholding details, are summarised below:

Ravin Gandhi's Rationale

Mr. Ravin Gandhi, based in Chicago, Illinois, USA, stated in his letter that he had already resigned from the Board of Directors of the company vide letter dated 12 May 2026, which was accepted by the company on the same date. He confirmed that he is no longer associated with the management or control of Hester Biosciences, directly or indirectly, and does not hold any position as a director or Key Managerial Personnel. He further stated that his shareholding is below the prescribed threshold and is held purely as a passive investment, with no intention to exercise control over the affairs of the company. Mr. Gandhi also confirmed compliance with the conditions under Regulation 31A(3)(b), including that he and persons related to him do not hold more than 10% of the total voting rights, and that there are no pending regulatory actions against him.

Bela Gandhi's Rationale

Ms. Bela Gandhi, also based in Chicago, USA, stated in her letter that she has not been involved in management and has not been associated with the management or control of the company, directly or indirectly, for the last 12 years. She does not hold any Board position or Key Managerial Personnel role, and her shareholding is held purely as a passive investment. Ms. Gandhi similarly confirmed satisfaction of the conditions under Regulation 31A(3)(b), including that she does not hold more than 10% of total voting rights along with related persons, exercises no control over the company's affairs, and that there are no pending regulatory actions against her.

Director Resignation and Alternate Directorship

The reclassification request by Mr. Ravin Gandhi follows his earlier resignation as Non-Executive Director of Hester Biosciences, effective 12 May 2026. His resignation was attributed to ongoing professional and personal commitments and his inability to devote sufficient time to the affairs of the company. As a direct consequence of his resignation, Ms. Nina Gandhi, who held the position of Alternate Director to Mr. Ravin Gandhi, also ceased to hold office with effect from 12 May 2026, in accordance with applicable provisions governing alternate directorships.

Regulatory Compliance

The intimation regarding the reclassification requests was signed and submitted by Vinod Mali, Company Secretary and Compliance Officer of Hester Biosciences Limited, on 15 May 2026. The disclosure pertaining to Mr. Ravin Gandhi's earlier resignation was made in accordance with Regulation 30 of the SEBI LODR Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated 30 January 2026. The company has confirmed it is processing the reclassification requests as per the provisions of Regulation 31A of the SEBI (LODR) Regulations, 2015.

Hester Biosciences Limited has announced an investor earnings conference call to discuss its financial results for the quarter and year ended March 31, 2026. The intimation was filed with stock exchanges on May 11, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call is scheduled for Friday, May 15, 2026, at 2:00 p.m. IST, and will be facilitated by ICICI Securities.

Conference Call Details

The earnings call will feature participation from the company's senior leadership. The following key details summarize the event:

Management Representatives

The conference call will be represented by the following members of Hester Biosciences' senior management:

• Mr. Rajiv Gandhi — CEO & Managing Director
• Ms. Priya Gandhi — Executive Director
• Mr. Ashish Desai — Chief Financial Officer

Call Coordination

ICICI Securities has designated the following coordinators to assist participants with the conference call:

The intimation was signed by Vinod Mali, Company Secretary & Compliance Officer of Hester Biosciences Limited, and submitted to both BSE Limited and the National Stock Exchange of India Limited on May 11, 2026.